^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    MALT1 protein inhibitor

    Related drugs:
    3d
    SGR-1505-101: Study of SGR-1505 in Mature B-Cell Neoplasms (clinicaltrials.gov)
    P1, N=98, Recruiting, Schrödinger, Inc. | N=52 --> 98 | Trial completion date: Mar 2026 --> Nov 2027 | Trial primary completion date: Mar 2026 --> Nov 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    SGR-1505
    28d
    A Phase 1 Dose-Escalation, Food Effect, and Drug-Drug Interaction Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MALT1 Inhibitor, SGR-1505, in Healthy Volunteers. (PubMed, Clin Pharmacol Drug Dev)
    Co-administration with posaconazole increased SGR-1505 exposure 3-fold...Asymptomatic, reversible indirect hyperbilirubinemia occurred, consistent with inhibition of UGT1A1. SGR-1505 was well-tolerated and exhibited favorable pharmacokinetic and pharmacodynamic properties, supporting further clinical development.
    P1 data • PK/PD data • Journal
    |
    IL2 (Interleukin 2) • MALT1 (MALT1 Paracaspase)
    |
    Noxafil (posaconazole) • SGR-1505
    4ms
    Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets (clinicaltrials.gov)
    P1, N=150, Recruiting, AbbVie | Trial completion date: Jun 2027 --> Jul 2029 | Trial primary completion date: Jun 2027 --> Jul 2029
    Trial completion date • Trial primary completion date • Adverse events • First-in-human
    4ms
    Accelerated In Silico Discovery of SGR-1505: A Potent MALT1 Allosteric Inhibitor for the Treatment of Mature B-Cell Malignancies. (PubMed, J Med Chem)
    Multiparameter optimization allowed efficient prioritization of molecules with good potency and drug-like properties during lead optimization, which led to the discovery of a highly potent MALT1 inhibitor, SGR-1505, with a well-balanced property profile. It demonstrated strong antitumor activity alone and in combination with BTK inhibitor in multiple in vivo B-cell lymphoma xenograft models and progressed to a phase 1 clinical trial in patients with mature B-cell neoplasms.
    Journal
    |
    CARD11 (Caspase Recruitment Domain Family Member 11) • MALT1 (MALT1 Paracaspase)
    |
    SGR-1505
    6ms
    ADITI-1: Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma (clinicaltrials.gov)
    P1, N=40, Recruiting, Aurigene Discovery Technologies Limited | Not yet recruiting --> Recruiting
    Enrollment open
    7ms
    Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets (clinicaltrials.gov)
    P1, N=150, Recruiting, AbbVie | N=100 --> 150
    Enrollment change • Adverse events
    8ms
    A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
    P1, N=226, Completed, Janssen Research & Development, LLC | Active, not recruiting --> Completed
    Trial completion
    |
    safimaltib (JNJ-6633)
    8ms
    Telaprevir attenuates caspase-11-dependent pyroptosis in mouse heart following ischemia/reperfusion via inhibition of MALT1/TRAF6 pathway. (PubMed, Toxicol Appl Pharmacol)
    Mechanistically, telaprevir inhibited the recruitment of TRAF6 by MALT1, concomitant with the reduced recruitment of caspase-11 by TRAF6, and in turn, attenuated caspase-11 K63 poly-ubiquitination and activation, which was further confirmed by knockdown of TRAF6. Based on these results, we concluded that telaprevir could protect mouse heart against I/R injury by reducing caspase-11-dependent pyroptosis through inhibition of MALT1/TRAF6 pathway.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • MALT1 (MALT1 Paracaspase) • TRAF6 (TNF Receptor Associated Factor 6)
    8ms
    Novel MALT1 Inhibitors for Treating Cancer. (PubMed, ACS Med Chem Lett)
    Provided herein are novel MALT1 inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, and processes for preparing such compounds.
    Journal
    |
    MALT1 (MALT1 Paracaspase)
    9ms
    Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies (clinicaltrials.gov)
    P1, N=50, Recruiting, Exscientia AI Limited
    New P1 trial
    11ms
    A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL (clinicaltrials.gov)
    P1, N=45, Completed, Janssen Research & Development, LLC | Active, not recruiting --> Completed
    Trial completion
    |
    Imbruvica (ibrutinib) • safimaltib (JNJ-6633)
    11ms
    A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P1, N=75, Completed, Janssen Research & Development, LLC | Active, not recruiting --> Completed | Trial completion date: Apr 2025 --> Jan 2025 | Trial primary completion date: Apr 2025 --> Jan 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    safimaltib (JNJ-6633) • JNJ-4681